Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

A PHASE I/IIa TRIAL USING CD19-TARGETED THIRD GENERATION CAR T CELLS FOR LYMPHOMA AND LEUKEMIA.

Enblad G, Karlsson H, Gammelgard G, Wenthe J, Lovgren T, Amini RM, Wikstrom KI, Essand M, Savoldo B, Hallbook H, Höglund M, Dotti G, Brenner MK, Hagberg H, Loskog A.

Clin Cancer Res. 2018 Aug 10. pii: clincanres.0426.2018. doi: 10.1158/1078-0432.CCR-18-0426. [Epub ahead of print]

PMID:
30097433
2.

CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30+ and CD30- Embryonal Carcinoma via Antigen-dependent and Fas/FasL Interactions.

Hong LK, Chen Y, Smith CC, Montgomery SA, Vincent BG, Dotti G, Savoldo B.

Cancer Immunol Res. 2018 Aug 7. pii: canimm.0065.2018. doi: 10.1158/2326-6066.CIR-18-0065. [Epub ahead of print]

PMID:
30087115
3.

Engineering PD-1-Presenting Platelets for Cancer Immunotherapy.

Zhang X, Wang J, Chen Z, Hu Q, Wang C, Yan J, Dotti G, Huang P, Gu Z.

Nano Lett. 2018 Jul 31. doi: 10.1021/acs.nanolett.8b02321. [Epub ahead of print]

PMID:
30063143
4.

Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells.

Morita D, Nishio N, Saito S, Tanaka M, Kawashima N, Okuno Y, Suzuki S, Matsuda K, Maeda Y, Wilson MH, Dotti G, Rooney CM, Takahashi Y, Nakazawa Y.

Mol Ther Methods Clin Dev. 2017 Dec 22;8:131-140. doi: 10.1016/j.omtm.2017.12.003. eCollection 2018 Mar 16.

5.

PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy.

Zhang X, Wang C, Wang J, Hu Q, Langworthy B, Ye Y, Sun W, Lin J, Wang T, Fine J, Cheng H, Dotti G, Huang P, Gu Z.

Adv Mater. 2018 May;30(22):e1707112. doi: 10.1002/adma.201707112. Epub 2018 Apr 14.

PMID:
29656492
6.

Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells.

Xiong W, Chen Y, Kang X, Chen Z, Zheng P, Hsu YH, Jang JH, Qin L, Liu H, Dotti G, Liu D.

Mol Ther. 2018 Apr 4;26(4):963-975. doi: 10.1016/j.ymthe.2018.01.020. Epub 2018 Mar 2.

7.

Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy.

Pellegatta S, Savoldo B, Di Ianni N, Corbetta C, Chen Y, Patané M, Sun C, Pollo B, Ferrone S, DiMeco F, Finocchiaro G, Dotti G.

Sci Transl Med. 2018 Feb 28;10(430). pii: eaao2731. doi: 10.1126/scitranslmed.aao2731. Erratum in: Sci Transl Med. 2018 Apr 4;10 (435):.

PMID:
29491184
8.

In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy.

Wang C, Wang J, Zhang X, Yu S, Wen D, Hu Q, Ye Y, Bomba H, Hu X, Liu Z, Dotti G, Gu Z.

Sci Transl Med. 2018 Feb 21;10(429). pii: eaan3682. doi: 10.1126/scitranslmed.aan3682.

PMID:
29467299
9.

T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.

Hu J, Sun C, Bernatchez C, Xia X, Hwu P, Dotti G, Li S.

Clin Cancer Res. 2018 Jun 15;24(12):2920-2934. doi: 10.1158/1078-0432.CCR-17-1365. Epub 2018 Feb 1.

PMID:
29391351
10.

Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.

Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, Carrum G, Ramos CA, Liu H, Wu MF, Marcogliese AN, Barese C, Zu Y, Lee DY, O'Connor O, Gee AP, Brenner MK, Heslop HE, Rooney CM.

J Clin Oncol. 2018 Apr 10;36(11):1128-1139. doi: 10.1200/JCO.2017.74.3179. Epub 2018 Jan 9.

PMID:
29315015
11.

A melanin-mediated cancer immunotherapy patch.

Ye Y, Wang C, Zhang X, Hu Q, Zhang Y, Liu Q, Wen D, Milligan J, Bellotti A, Huang L, Dotti G, Gu Z.

Sci Immunol. 2017 Nov 10;2(17). pii: eaan5692. doi: 10.1126/sciimmunol.aan5692.

PMID:
29127106
12.

Innovative Therapy, Monoclonal Antibodies and Beyond.

Di Nicola M, Apetoh L, Bellone M, Colombo MP, Dotti G, Ferrone S, Muscolini M, Hiscott J, Anichini A, Pupa SM, Braud F, Del Vecchio M.

Cytokine Growth Factor Rev. 2017 Dec;38:1-9. doi: 10.1016/j.cytogfr.2017.10.002. Epub 2017 Oct 5.

PMID:
29029813
13.

Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.

Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, Bollard CM, Chang BH, Rooney CM, Brenner MK, Heslop HE, Dotti G, Savoldo B.

J Clin Invest. 2017 Sep 1;127(9):3462-3471. doi: 10.1172/JCI94306. Epub 2017 Aug 14.

14.

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.

Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, Gagea M, Banerjee P, Cai R, Bdaiwi MH, Basar R, Muftuoglu M, Li L, Marin D, Wierda W, Keating M, Champlin R, Shpall E, Rezvani K.

Leukemia. 2018 Feb;32(2):520-531. doi: 10.1038/leu.2017.226. Epub 2017 Jul 20.

PMID:
28725044
15.

Chimeric antigen receptor T-cells for B-cell malignancies.

Lichtman EI, Dotti G.

Transl Res. 2017 Sep;187:59-82. doi: 10.1016/j.trsl.2017.06.011. Epub 2017 Jun 29. Review.

PMID:
28719798
16.

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.

Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, Mehta B, Zhang H, Mahmood N, Tashiro H, Heslop HE, Dotti G, Rooney CM, Brenner MK.

Mol Ther. 2017 Sep 6;25(9):2214-2224. doi: 10.1016/j.ymthe.2017.05.012. Epub 2017 Jun 9.

PMID:
28602436
17.

Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells.

Schmueck-Henneresse M, Omer B, Shum T, Tashiro H, Mamonkin M, Lapteva N, Sharma S, Rollins L, Dotti G, Reinke P, Volk HD, Rooney CM.

J Immunol. 2017 Jul 1;199(1):348-362. doi: 10.4049/jimmunol.1601494. Epub 2017 May 26.

18.

Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.

Krenciute G, Prinzing BL, Yi Z, Wu MF, Liu H, Dotti G, Balyasnikova IV, Gottschalk S.

Cancer Immunol Res. 2017 Jul;5(7):571-581. doi: 10.1158/2326-6066.CIR-16-0376. Epub 2017 May 26.

19.

HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.

Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S.

JAMA Oncol. 2017 Aug 1;3(8):1094-1101. doi: 10.1001/jamaoncol.2017.0184.

20.

Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.

Diaconu I, Ballard B, Zhang M, Chen Y, West J, Dotti G, Savoldo B.

Mol Ther. 2017 Mar 1;25(3):580-592. doi: 10.1016/j.ymthe.2017.01.011. Epub 2017 Feb 8.

21.

Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.

Tanaka M, Tashiro H, Omer B, Lapteva N, Ando J, Ngo M, Mehta B, Dotti G, Kinchington PR, Leen AM, Rossig C, Rooney CM.

Clin Cancer Res. 2017 Jul 15;23(14):3499-3509. doi: 10.1158/1078-0432.CCR-16-2138. Epub 2017 Feb 9.

22.

Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.

Li W, Guo L, Rathi P, Marinova E, Gao X, Wu MF, Liu H, Dotti G, Gottschalk S, Metelitsa LS, Heczey A.

Hum Gene Ther. 2017 May;28(5):437-448. doi: 10.1089/hum.2016.025. Epub 2016 Aug 16.

23.

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.

Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N.

J Clin Invest. 2016 Aug 1;126(8):3036-52. doi: 10.1172/JCI83416. Epub 2016 Jul 18.

24.

Glycolysis determines dichotomous regulation of T cell subsets in hypoxia.

Xu Y, Chaudhury A, Zhang M, Savoldo B, Metelitsa LS, Rodgers J, Yustein JT, Neilson JR, Dotti G.

J Clin Invest. 2016 Jul 1;126(7):2678-88. doi: 10.1172/JCI85834. Epub 2016 Jun 13.

25.

Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.

Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Brenner MK, Heslop HE, Dotti G.

J Clin Invest. 2016 Jul 1;126(7):2588-96. doi: 10.1172/JCI86000. Epub 2016 Jun 6.

26.

A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.

Ma Q, Garber HR, Lu S, He H, Tallis E, Ding X, Sergeeva A, Wood MS, Dotti G, Salvado B, Ruisaard K, Clise-Dwyer K, John LS, Rezvani K, Alatrash G, Shpall EJ, Molldrem JJ.

Cytotherapy. 2016 Aug;18(8):985-94. doi: 10.1016/j.jcyt.2016.05.001. Epub 2016 Jun 2.

27.

Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.

Sun C, Dotti G, Savoldo B.

Blood. 2016 Jun 30;127(26):3350-9. doi: 10.1182/blood-2015-12-629089. Epub 2016 May 20. Review.

28.

CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.

Tian G, Courtney AN, Jena B, Heczey A, Liu D, Marinova E, Guo L, Xu X, Torikai H, Mo Q, Dotti G, Cooper LJ, Metelitsa LS.

J Clin Invest. 2016 Jun 1;126(6):2341-55. doi: 10.1172/JCI83476. Epub 2016 May 16.

29.

Chimeric Antigen Receptors for Cancer Immunotherapy.

Geldres C, Savoldo B, Dotti G.

Methods Mol Biol. 2016;1393:75-86. doi: 10.1007/978-1-4939-3338-9_7.

PMID:
27033217
30.

GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.

Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD, Lewis ID, Brenner MK, Brown MP.

Mol Ther. 2016 Jun;24(6):1135-1149. doi: 10.1038/mt.2016.63. Epub 2016 Mar 29.

31.

Chimeric antigen receptor-redirected T cells return to the bench.

Geldres C, Savoldo B, Dotti G.

Semin Immunol. 2016 Feb;28(1):3-9. doi: 10.1016/j.smim.2015.12.001. Epub 2016 Jan 12. Review.

32.

Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation.

Zhou X, Naik S, Dakhova O, Dotti G, Heslop HE, Brenner MK.

Mol Ther. 2016 Apr;24(4):823-31. doi: 10.1038/mt.2015.234. Epub 2015 Dec 28.

33.

Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors.

Karlsson H, Svensson E, Gigg C, Jarvius M, Olsson-Strömberg U, Savoldo B, Dotti G, Loskog A.

PLoS One. 2015 Dec 23;10(12):e0144787. doi: 10.1371/journal.pone.0144787. eCollection 2015.

34.

Selection bias: maintaining less-differentiated T cells for adoptive immunotherapy.

Xu Y, Dotti G.

J Clin Invest. 2016 Jan;126(1):35-7. doi: 10.1172/JCI85631. Epub 2015 Dec 14.

35.

Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch.

Chang EC, Liu H, West JA, Zhou X, Dakhova O, Wheeler DA, Heslop HE, Brenner MK, Dotti G.

Mol Ther. 2016 Apr;24(4):736-45. doi: 10.1038/mt.2015.217. Epub 2015 Dec 7.

36.

Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.

Krenciute G, Krebs S, Torres D, Wu MF, Liu H, Dotti G, Li XN, Lesniak MS, Balyasnikova IV, Gottschalk S.

Mol Ther. 2016 Feb;24(2):354-363. doi: 10.1038/mt.2015.199. Epub 2015 Oct 30.

37.
38.

Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.

Wang Y, Geldres C, Ferrone S, Dotti G.

Expert Opin Ther Targets. 2015;19(10):1339-50. doi: 10.1517/14728222.2015.1068759. Epub 2015 Jul 18. Review.

PMID:
26190756
39.

Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers.

Hoyos V, Del Bufalo F, Yagyu S, Ando M, Dotti G, Suzuki M, Bouchier-Hayes L, Alemany R, Brenner MK.

Mol Ther. 2015 Sep;23(9):1497-506. doi: 10.1038/mt.2015.110. Epub 2015 Jun 18.

40.

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation.

Zhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT, Durett AG, Dakhova O, Savoldo B, Di Stasi A, Spencer DM, Lin YF, Liu H, Grilley BJ, Gee AP, Rooney CM, Heslop HE, Brenner MK.

Blood. 2015 Jun 25;125(26):4103-13. doi: 10.1182/blood-2015-02-628354. Epub 2015 May 14.

41.

Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors.

Nishio N, Dotti G.

Oncoimmunology. 2015 Mar 6;4(2):e988098. eCollection 2015 Feb. Review.

42.

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.

Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, Heslop HE, Brenner MK, Rooney CM, Ramos CA.

Blood. 2015 Jun 18;125(25):3905-16. doi: 10.1182/blood-2015-01-621474. Epub 2015 May 4.

43.

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes.

Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, Ittmann MM, Marchetti D, Dotti G.

Nat Med. 2015 May;21(5):524-9. doi: 10.1038/nm.3833. Epub 2015 Apr 13.

44.

Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.

Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, Gray T, Wu MF, Liu H, Hicks J, Rainusso N, Dotti G, Mei Z, Grilley B, Gee A, Rooney CM, Brenner MK, Heslop HE, Wels WS, Wang LL, Anderson P, Gottschalk S.

J Clin Oncol. 2015 May 20;33(15):1688-96. doi: 10.1200/JCO.2014.58.0225. Epub 2015 Mar 23.

45.

Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application.

Sun J, Huye LE, Lapteva N, Mamonkin M, Hiregange M, Ballard B, Dakhova O, Raghavan D, Durett AG, Perna SK, Omer B, Rollins LA, Leen AM, Vera JF, Dotti G, Gee AP, Brenner MK, Myers DG, Rooney CM.

J Immunother Cancer. 2015 Feb 18;3:5. doi: 10.1186/s40425-015-0049-1. eCollection 2015.

46.

K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo.

Caruana I, Weber G, Ballard BC, Wood MS, Savoldo B, Dotti G.

Clin Cancer Res. 2015 Jul 1;21(13):2952-62. doi: 10.1158/1078-0432.CCR-14-2998. Epub 2015 Feb 17.

47.

Overcoming the toxicity hurdles of genetically targeted T cells.

Casucci M, Hawkins RE, Dotti G, Bondanza A.

Cancer Immunol Immunother. 2015 Jan;64(1):123-30. doi: 10.1007/s00262-014-1641-9. Epub 2014 Dec 9. Review.

PMID:
25488419
48.

From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies.

Caruana I, Diaconu I, Dotti G.

Semin Oncol. 2014 Oct;41(5):661-6. doi: 10.1053/j.seminoncol.2014.08.005. Epub 2014 Aug 12. Review.

49.

Survivin-specific T cell receptor targets tumor but not T cells.

Arber C, Feng X, Abhyankar H, Romero E, Wu MF, Heslop HE, Barth P, Dotti G, Savoldo B.

J Clin Invest. 2015 Jan;125(1):157-68. doi: 10.1172/JCI75876. Epub 2014 Nov 21.

50.

BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.

Gargett T, Fraser CK, Dotti G, Yvon ES, Brown MP.

J Immunother. 2015 Jan;38(1):12-23. doi: 10.1097/CJI.0000000000000061.

PMID:
25415284

Supplemental Content

Support Center